Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Targeting of the G-CSF Receptor Reduces Neutrophil Trafficking and Joint Inflammation in Antibody-Mediated Inflammatory Arthritis.
Campbell IK, Leong D, Edwards KM, Rayzman V, Ng M, Goldberg GL, Wilson NJ, Scalzo-Inguanti K, Mackenzie-Kludas C, Lawlor KE, Wicks IP, Brown LE, Baz Morelli A, Panousis C, Wilson MJ, Nash AD, McKenzie BS, Andrews AE. Campbell IK, et al. Among authors: rayzman v. J Immunol. 2016 Dec 1;197(11):4392-4402. doi: 10.4049/jimmunol.1600121. Epub 2016 Nov 2. J Immunol. 2016. PMID: 27807194
A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.
Larsson M, Rayzman V, Nolte MW, Nickel KF, Björkqvist J, Jämsä A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broomé M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renné T. Larsson M, et al. Among authors: rayzman v. Sci Transl Med. 2014 Feb 5;6(222):222ra17. doi: 10.1126/scitranslmed.3006804. Sci Transl Med. 2014. PMID: 24500405
CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.
Panousis C, Dhagat U, Edwards KM, Rayzman V, Hardy MP, Braley H, Gauvreau GM, Hercus TR, Smith S, Sehmi R, McMillan L, Dottore M, McClure BJ, Fabri LJ, Vairo G, Lopez AF, Parker MW, Nash AD, Wilson NJ, Wilson MJ, Owczarek CM. Panousis C, et al. Among authors: rayzman v. MAbs. 2016;8(3):436-53. doi: 10.1080/19420862.2015.1119352. Epub 2015 Dec 14. MAbs. 2016. PMID: 26651396 Free PMC article.
Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation.
Cao H, Biondo M, Lioe H, Busfield S, Rayzman V, Nieswandt B, Bork K, Harrison LC, Auyeung P, Farkas H, Csuka D, Pelzing M, Dower S, Wilson MJ, Nash A, Nolte MW, Panousis C. Cao H, et al. Among authors: rayzman v. J Allergy Clin Immunol. 2018 Oct;142(4):1355-1358. doi: 10.1016/j.jaci.2018.06.014. Epub 2018 Jun 21. J Allergy Clin Immunol. 2018. PMID: 29936101 No abstract available.
Activated Coagulation FXII: A Unique Target for In Vivo Molecular Imaging.
Walsh APG, Yu E, McFadyen JD, Bongcaron V, Moon MJ, Huang A, Arthur JF, Muir IL, Rayzman V, Panousis C, Wang X, Peter K. Walsh APG, et al. Among authors: rayzman v. Arterioscler Thromb Vasc Biol. 2023 Jun;43(6):1031-1040. doi: 10.1161/ATVBAHA.122.318883. Epub 2023 Apr 20. Arterioscler Thromb Vasc Biol. 2023. PMID: 37078286
Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.
Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM. Panousis C, et al. Among authors: rayzman vm. Br J Cancer. 2005 Mar 28;92(6):1069-77. doi: 10.1038/sj.bjc.6602470. Br J Cancer. 2005. PMID: 15770208 Free PMC article.